Fig. 3: PPV and NPV for probability of pCR by the percent tumor volume reduction after two cycles of NAST in the discovery cohort (A, B) and the validation cohort (C, D). | npj Breast Cancer

Fig. 3: PPV and NPV for probability of pCR by the percent tumor volume reduction after two cycles of NAST in the discovery cohort (A, B) and the validation cohort (C, D).

From: Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer

Fig. 3: PPV and NPV for probability of pCR by the percent tumor volume reduction after two cycles of NAST in the discovery cohort (A, B) and the validation cohort (C, D).

PPV was 82% in the discovery cohort (A) and 83% in the validation cohort (C) at tumor volume reduction > 80% (vertical line). NPV was 91% in the discovery cohort (B) and 84% in the validation cohort (D) at tumor volume reduction < 55% (vertical line). The dotted lines represent 95% confidence intervals. Area under the curve (AUC) 0.82 (0.74-0.90, p < 0.0001) in the discovery cohort and 0.81(0.73-0.89, p < 0.0001) in the validation cohort.

Back to article page